Selection of 4 products from
£10.49 to £37.99
Meloxidyl is supplied as a liquid to add to food. It is a non-steroidal anti-inflammatory drug prescribed for dogs and cats primarily to treat musculo-skeletal problems such as osteoarthrits. Meloxidyl reduces pain and inflammation in other conditions too, and can be prescribed for any condition where these properties are likely to be of benefit.
A pale yellow suspension containing 0.5 mg/ml meloxicam as active ingredient and 2mg/ml of sodium benzoate as a preservative.
Meloxidyl® 0.5 mg/ml oral suspension for cats is a non-steroidal anti-inflammatory drug (NSAID) for use in cats for:
- the alleviation of inflammation and pain in chronic musculo-skeletal disorders in cats
- the alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.
Post-operative pain and inflammation following surgical procedures:
After initial treatment with meloxicam 2 mg/ml solution for injection for cats, continue treatment 24 hours later with MELOXIDYL 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg bodyweight. The oral follow-up dose may be administered once daily (at 24 hour intervals) for up to four days.
Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day.
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.
Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded.
Shake well before use. To be administered orally either mixed with food or directly into the mouth.
The suspension can be given using the measuring syringe provided in the package.
The syringe fits onto the bottle and has a kg-body weight scale (from 1 kg to 10 kg) which corresponds to the maintenance dose. Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.
A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.
Avoid introduction of contamination during use.
Do not use in pregnant or lactating animals.
Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in cats less than 6 weeks of age.
Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
Post-operative pain and inflammation following surgical procedures: In case additional pain relief is required, multimodal pain therapy should be considered.
Chronic musculoskeletal disorders: Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. MELOXIDYL must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.
Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels. In case of overdose, adverse reactions are expected to be more severe and more frequent. In the case of overdose symptomatic treatment should be initiated.
This veterinary medicinal product does not require any special storage conditions.
Use within 6 months once opened.
Any unused product or waste materials should be disposed of in accordance with local requirements.
Cardboard box containing 15 ml bottle with one measuring syringe.
The measuring syringe has a kg-body weight scale for cats (1 to 10 kg).
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).
If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed.
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins.
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Five major metabolites have been identified. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. As for other species investigated, the main pathway of meloxicam biotransformation in cat is oxidation and there are no pharmacologically active metabolites.
Meloxicam is eliminated with a half-life of 24 hours. The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21% of the recovered dose is eliminated in urine (2% as unchanged meloxicam, 19% as metabolites) and 79% in the faeces (49% as unchanged meloxicam, 30% as metabolites).
Ceva Santé Animale - France
Meloxidyl cat 4ml:
All prices include VAT where applicable.
Below are some recent questions we've received regarding Meloxidyl Oral Liquid for Dogs and Cats, including answers from our team.Ask Your Own Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VioPoints are a way for us to say thank you for purchasing from VioVet.
You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VioPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.